(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 August 2019 (15.08.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/157324 A1

(51) International Patent Classification:
A61K 38/47 (2006.01) *C12N 15/11* (2006.01)
C12N 9/16 (2006.01) *C12N 15/90* (2006.01)
C12N 9/22 (2006.01)

(21) International Application Number:
PCT/US2019/017273

(22) International Filing Date:
08 February 2019 (08.02.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/628,016	08 February 2018 (08.02.2018)	US
62/728,226	07 September 2018 (07.09.2018)	US
62/758,786	12 November 2018 (12.11.2018)	US
62/795,937	23 January 2019 (23.01.2019)	US
62/802,092	06 February 2019 (06.02.2019)	US

(71) Applicant: **SANGAMO THERAPEUTICS, INC.** [US/US]; 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(72) Inventors: **DEKELVER, Russell**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **KRIVEGA, Ivan**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **MILLER, Jeffrey C.**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US). **ZHANG, Lei**; c/o Sangamo Therapeutics, Inc., 501 Canal Blvd., Suite A100, Richmond, California 94804 (US).

(74) Agent: **PASTERNAK, Dahna**; Pasternak Patent Law, 1900 Embarcadero Rd., Suite 211, Palo Alto, California 94303 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ENGINEERED TARGET SPECIFIC NUCLEASES




FIG. 1A

(57) Abstract: Described herein are engineered nucleases comprising mutations in the cleavage domain (*e.g., Fok*I or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.

WO 2019/157324 A1